Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,900 | 11 | 99.1% |
| Food and Beverage | $123.25 | 1 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $7,400 | 9 | $0 (2021) |
| Amgen Inc. | $6,500 | 2 | $0 (2021) |
| Carl Zeiss Meditec, Inc. | $123.25 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $5,200 | 2 | Amgen Inc. ($4,500) |
| 2020 | $2,600 | 2 | Amgen Inc. ($2,000) |
| 2019 | $1,600 | 2 | PFIZER INC. ($1,600) |
| 2018 | $2,700 | 4 | PFIZER INC. ($2,700) |
| 2017 | $1,923 | 2 | PFIZER INC. ($1,800) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/19/2021 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| 04/12/2021 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2020 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 03/30/2020 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2019 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2019 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2018 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2018 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2018 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2018 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2017 | Carl Zeiss Meditec, Inc. | PLEX Elite 9000 (Device) | Food and Beverage | In-kind items and services | $123.25 | General |
| Category: Optical Tomographer | ||||||
| 09/11/2017 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 586 | 901 | $210,537 | $43,708 |
| 2022 | 10 | 713 | 1,068 | $357,855 | $66,302 |
| 2021 | 11 | 697 | 1,072 | $347,650 | $63,388 |
| 2020 | 9 | 746 | 1,111 | $278,015 | $54,226 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 201 | 293 | $36,873 | $20,392 | 55.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 45 | 167 | $111,888 | $11,438 | 10.2% |
| 92134 | Imaging of retina | Office | 2023 | 193 | 288 | $38,304 | $4,889 | 12.8% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 70 | 73 | $10,345 | $3,314 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 15 | $2,929 | $1,620 | 55.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $3,584 | $1,194 | 33.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 11 | 12 | $3,420 | $396.36 | 11.6% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 16 | 17 | $1,734 | $303.28 | 17.5% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 20 | 20 | $1,460 | $161.98 | 11.1% |
| 67028 | Injection of drug into eye | Office | 2022 | 57 | 221 | $147,852 | $15,297 | 10.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 136 | 204 | $24,765 | $14,828 | 59.9% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Office | 2022 | 15 | 15 | $98,520 | $13,817 | 14.0% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 175 | 182 | $25,846 | $9,439 | 36.5% |
| 92134 | Imaging of retina | Office | 2022 | 193 | 306 | $40,698 | $5,824 | 14.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 33 | $5,718 | $3,658 | 64.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $4,928 | $2,115 | 42.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 13 | 14 | $3,990 | $471.00 | 11.8% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 48 | 48 | $3,192 | $468.08 | 14.7% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 23 | 23 | $2,346 | $385.21 | 16.4% |
| 67028 | Injection of drug into eye | Office | 2021 | 61 | 240 | $159,840 | $15,891 | 9.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 132 | 208 | $25,198 | $15,481 | 61.4% |
| 67042 | Removal of membrane from the retina, pars plana approach with removal of internal limiting membrane of retina | Office | 2021 | 11 | 11 | $72,248 | $10,359 | 14.3% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 175 | 186 | $27,477 | $9,063 | 33.0% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 187 | 295 | $43,327 | $5,525 | 12.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 27 | 27 | $4,799 | $3,171 | 66.1% |
About Dr. Mark Johnson, MD
Dr. Mark Johnson, MD is a Ophthalmology healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083622773.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Johnson, MD has received a total of $14,023 in payments from pharmaceutical and medical device companies, with $5,200 received in 2021. These payments were reported across 12 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($13,900).
As a Medicare-enrolled provider, Johnson has provided services to 2,742 Medicare beneficiaries, totaling 4,152 services with total Medicare billing of $227,624. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Practice Information
- Specialty Ophthalmology
- Location Ann Arbor, MI
- Active Since 08/04/2006
- Last Updated 01/19/2021
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1083622773
Products in Payments
- XALKORI (Drug) $7,400
- PLEX Elite 9000 (Device) $123.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Ann Arbor
Dr. Yannis Paulus, M.d, M.D
Ophthalmology — Payments: $85,252
Dr. Amanda Bicket, M.d, M.D
Ophthalmology — Payments: $51,093
Kanishka Jayasundera
Ophthalmology — Payments: $45,504
Marguerite Weinert, Md, MD
Ophthalmology — Payments: $23,457
Christine Nelson, Md, MD
Ophthalmology — Payments: $12,770
Abigail Fahim, M.d, M.D
Ophthalmology — Payments: $12,616